The Challenges of Autologous Cell Therapy: Systemic Anti-thrombotic Therapies Interfering with Serum Coagulation May Disable Autologous Serum-Containing Cell Products for Therapeutical Use

Journal of Cardiovascular Translational Research

Volumn 7, Issue 7, 2014, Pages 644-650

  Seeger, Florian H ^a   Rasper, Tina ^a   Bönig, Halvard ^a   Assmus, Birgit ^a   Zeiher, Andreas M ^a   Dimmeler, Stefanie ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Acute myocardial infarction; Anti thrombotic therapy; BMC; Cell preparation; Cell therapy; Plasma; Serum

Indexed keywords

HEPARIN; PROCOAGULANT; RECOMBINANT GROWTH FACTOR; CULTURE MEDIUM; FIBRINOLYTIC AGENT;

ACUTE HEART INFARCTION; ANTICOAGULANT THERAPY; ARTICLE; AUTOLOGOUS CELL THERAPY; BLOOD CLOTTING; BLOOD SAMPLING; BONE MARROW DERIVED MONONUCLEAR CELL; CELL AGGREGATION; CELL FUNCTION; CELL ISOLATION; CELL THERAPY; DRUG EFFECT; EX VIVO STUDY; HUMAN; LOW DRUG DOSE; SERUM; SYSTEMIC THERAPY; AUTOTRANSPLANTATION; BLOOD CLOTTING TEST; BONE MARROW TRANSPLANTATION; CELL CULTURE; CULTURE MEDIUM; CULTURE TECHNIQUE; DEVICES; DISPOSABLE EQUIPMENT; DRUG EFFECTS; EQUIPMENT DESIGN; PROCEDURES; STEM CELL TRANSPLANTATION; TIME;

BLOOD COAGULATION; BLOOD COAGULATION TESTS; BLOOD SPECIMEN COLLECTION; BONE MARROW TRANSPLANTATION; CELL CULTURE TECHNIQUES; CELLS, CULTURED; CULTURE MEDIA; DISPOSABLE EQUIPMENT; EQUIPMENT DESIGN; FIBRINOLYTIC AGENTS; HEPARIN; HUMANS; SERUM; STEM CELL TRANSPLANTATION; TIME FACTORS; TRANSPLANTATION, AUTOLOGOUS;

EID: 84919764862     PISSN: 19375387     EISSN: 19375395     Source Type: Journal    
DOI: 10.1007/s12265-014-9584-2     Document Type: Article

References (21)

1. Schachinger, V., et al. (2006). Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. New England Journal of Medicine, 355(12), 1210–1221.
2. Jeevanantham, V., et al. (2012). Adult bone marrow cell therapy improves survival and induces long-term improvement in cardiac parameters: a systematic review and meta-analysis. Circulation, 126(5), 551–568.
3. Delewi, R. et al. (2013). Impact of intracoronary bone marrow cell therapy on left ventricular function in the setting of ST-segment elevation myocardial infarction: a collaborative meta-analysis. European Heart Journal.
4. Lunde, K., et al. (2006). Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction. New England Journal of Medicine, 355(12), 1199–1209.
5. Seeger, F. H., et al. (2007). Cell isolation procedures matter: a comparison of different isolation protocols of bone marrow mononuclear cells used for cell therapy in patients with acute myocardial infarction. European Heart Journal, 28(6), 766–772.
6. Assmus, B., et al. (2002). Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction (TOPCARE-AMI). Circulation, 106(24), 3009–3017.
7. Leistner, D. M., & Zeiher, A. M. (2012). Novel avenues for cell therapy in acute myocardial infarction. Circulation Research, 110(2), 195–197.
8. Britten, M. B., et al. (2003). Infarct remodeling after intracoronary progenitor cell treatment in patients with acute myocardial infarction (TOPCARE-AMI): mechanistic insights from serial contrast-enhanced magnetic resonance imaging. Circulation, 108(18), 2212–2218.
9. Assmus, B., et al. (2007). Transcoronary transplantation of functionally competent BMCs is associated with a decrease in natriuretic peptide serum levels and improved survival of patients with chronic postinfarction heart failure: results of the TOPCARE-CHD Registry. Circulation Research, 100(8), 1234–1241.
10. Assmus, B., et al. (2014). Long-term clinical outcome after intracoronary application of bone marrow-derived mononuclear cells for acute myocardial infarction: migratory capacity of administered cells determines event-free survival. European Heart Journal.
11. Steg, P. G., et al. (2012). ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. European Heart Journal, 33(20), 2569–2619.
12. Huat, T. J., et al. (2014). IGF-1 enhances cell proliferation and survival during early differentiation of mesenchymal stem cells to neural progenitor-like cells. BMC Neuroscience, 15(1), 91.
13. Thum, T., et al. (2007). Age-dependent impairment of endothelial progenitor cells is corrected by growth-hormone-mediated increase of insulin-like growth-factor-1. Circulation Research, 100(3), 434–443.
14. Cai, L., et al. (2007). Suppression of hepatocyte growth factor production impairs the ability of adipose-derived stem cells to promote ischemic tissue revascularization. Stem Cells, 25(12), 3234–3243.
15. Li, N., Pasha, Z., & Ashraf, M. (2014). Reversal of ischemic cardiomyopathy with Sca-1+ stem cells modified with multiple growth factors. PLoS One, 9(4), e93645.
16. Guo, Y., Graham-Evans, B., & Broxmeyer, H. E. (2006). Murine embryonic stem cells secrete cytokines/growth modulators that enhance cell survival/anti-apoptosis and stimulate colony formation of murine hematopoietic progenitor cells. Stem Cells, 24(4), 850–856.
17. Broxmeyer, H. E., et al. (2003). Stromal cell-derived factor-1/CXCL12 directly enhances survival/antiapoptosis of myeloid progenitor cells through CXCR4 and G(alpha)i proteins and enhances engraftment of competitive, repopulating stem cells. Journal of Leukocyte Biology, 73(5), 630–638.
18. Iwaguro, H., et al. (2002). Endothelial progenitor cell vascular endothelial growth factor gene transfer for vascular regeneration. Circulation, 105(6), 732–738.
19. Seeger, F. H., Zeiher, A. M., & Dimmeler, S. (2007). Cell-enhancement strategies for the treatment of ischemic heart disease. Nature Clinical Practice. Cardiovascular Medicine, 4(Suppl 1), S110–S113.
20. Burchfield, J. S., & Dimmeler, S. (2008). Role of paracrine factors in stem and progenitor cell mediated cardiac repair and tissue fibrosis. Fibrogenesis & Tissue Repair, 1(1), 4.
21. Ogawa, M. (1993). Differentiation and proliferation of hematopoietic stem cells. Blood, 81(11), 2844–2853.